What do TSECs provide in the menopausal hormone therapy?

References

• Valera MC, Gourdy P, Trémollières F, et al. From the women’s health initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition. Maturitas. 2015;82:274–277.
   PubMed Web of Science ®Google Scholar
• Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas. 2016;91:25–35.
   PubMed Web of Science ®Google Scholar
• Peng L, Luo Q, Lu H. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e8659.
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/002314/WC500181566.pdf
   Google Scholar
• FDA Guidance: www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm071643.pdf
   Google Scholar
• Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. 2013;76:213–220.
   PubMed Web of Science ®Google Scholar
• http://cebgrade.mcmaster.ca/
   Google Scholar
• Kharode Y, Bodine PV, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008;149:6084–6091.
   PubMed Web of Science ®Google Scholar
• Flannery CA, Fleming AG, Choe GH, et al. Endometrial cancer-associated FGF18 expression is reduced by bazedoxifene in human endometrial stromal cells in vitro and in murine endometrium. Endocrinology. 2016;157:3699–3708.
   PubMed Web of Science ®Google Scholar
• Han SJ, Begum K, Foulds CE, et al. The dual estrogen receptor α inhibitory effects of the tissue-selective estrogen complex for endometrial and breast safety. Mol Pharmacol. 2016;89:14–26.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025–1038.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116–1124.
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17:281–289.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric. 2013;16:338–346.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99:E189–E198.
   PubMed Web of Science ®Google Scholar
• Yu H, Racketa J, Chines AA, et al. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women. Climacteric. 2013;16:252–257.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause. 2014;21:252–259.
   PubMed Web of Science ®Google Scholar
• Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009;63:329–335.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Bushmakin AG, Racketa J, et al. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling. Menopause. 2014;21:243–251.
   PubMed Web of Science ®Google Scholar
• Bushmakin AG, Abraham L, Pinkerton JV, et al. Evaluation of the measurement model and clinically important differences for menopause specific quality of life associated with bazedoxifene/conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women. Maturitas. 2016;94:173–179.
   PubMedGoogle Scholar
• Abraham L, Pinkerton JV, Messig M, et al. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014;78:212–218.
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Shi H, Mirkin S, et al. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens. Menopause. 2013;20:1126–1132.
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifeno/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13:132–140.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Bushmakin AG, Komm BS, et al. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning. Maturitas. 2017;100:57–63.
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Palacios S, Ryan KA, et al. Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause. 2016;23:1083–1091.
   PubMed Web of Science ®Google Scholar
• Palacios S, Arias L, Lavenberg J, et al. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population. Climacteric. 2016;19:261–267.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Abraham L, Bushmakin AG, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. J Womens Health. 2014;23:18–28.
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92:1018–1024.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Pinkerton JV, Kagan R, et al. Gynecologic safety of conjugated estrogens plus bazedoxifene: pooled analysis of five phase 3 trials. J Womens Health. 2016;25:431–442.
   PubMed Web of Science ®Google Scholar
• Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric. 2015;18:470–482.
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology. 2009;150:1897–1903.
   PubMed Web of Science ®Google Scholar
• Song Y, Santen RJ, Wang JP, et al. Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro. Endocrinology. 2013;154:656–665.
   PubMed Web of Science ®Google Scholar
• Madak-Erdogan Z, Gong P, Katzenellenbogen BS. Differential utilization of nuclear and extranuclear receptor signaling pathways in the actions of estrogens, SERMs, and a tissue-selective estrogen complex (TSEC). J Steroid Biochem Mol Biol. 2016;158:198–206.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013;121:959–968.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness afterinitiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat. 2012;131:969–979.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Taylor H, Pan K, et al. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause 2010;17:1221–1222.
   Web of Science ®Google Scholar
• Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause. 2013;20:138–145.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–111.
   PubMed Web of Science ®Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, et al. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010;126:483–489.
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grénman S, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol. 2016;55:188–192.
   PubMed Web of Science ®Google Scholar
• Siegelmann-Danieli N, Katzir I, Landes JV, et al. Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Res Treat. 2017;167:257–262.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–1934.
   PubMed Web of Science ®Google Scholar
• Komm BS, Thompson JR, Mirkin S. Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials. Climacteric. 2015;18:503–511.
   PubMed Web of Science ®Google Scholar
• Sites CK, L’Hommedieu GD, Toth MJ, et al. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2005;90:2701–2707.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161:249–260.
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113:65–73.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009;12:445–453.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310:1353–1368.
   PubMed Web of Science ®Google Scholar
• Krämer EA, Seeger H, Krämer B, et al. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod Biol. 2006;129:77–83.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol. 2015;1:296–305.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840–845.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005;84:485–491.
   PubMed Web of Science ®Google Scholar
• Lundström E, Wilczek B, Von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric. 2001;4:42–48.
   PubMedGoogle Scholar
• Stuedal A, Ma H, Bjørndal H, et al. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric. 2009;12:248–258.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Abad P, Baró F, et al. Spanish Menopause Society position statement: use of tibolone in postmenopausal women. Menopause. 2013;20:754–760.
   PubMed Web of Science ®Google Scholar
• Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007;10:3–10.
   PubMed Web of Science ®Google Scholar
• De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316–337.
   PubMed Web of Science ®Google Scholar
• Palacios S, Mejía A. Progestogen safety and tolerance in hormonal replacement therapy. Expert Opin Drug Saf. 2016;15:1515–1525.
   PubMed Web of Science ®Google Scholar
• Sánchez-Borrego R, Mendoza N, Beltrán E, et al. Position of the Spanish menopause society regarding the management of menopausal symptoms in breast cancer patients. Maturitas. 2013;75:294–300.
   PubMed Web of Science ®Google Scholar